Generation Bio EBIT

The latest EBIT for GBIO is $-65M as of September 2025. That compares with $-100M in the prior-year period — up 35.5% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Generation Bio's historical trend and sector peers before judging valuation or financial health.

Over the past year, GBIO's EBIT moved from $-100M to $-65M — a 35.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Generation Bio's operating scale or balance-sheet position.

Against Healthcare companies, GBIO currently prints $-65M for EBIT, while the sector average sits near $23B. That is roughly 100.3% below the sector mean. Large gaps often invite a closer look at Generation Bio's growth, margins, and balance sheet.

A EBIT figure of $-65M for GBIO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting GBIO's EBIT ($-65M), review year-over-year change from $-100M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.